Company intelligence / Profile preview

US Biotest, Inc.

San Luis Obispo, California, United Statesusbiotest.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

US Biotest, Inc. is an active U.S.-based clinical-stage biotech/CRO focused on developing peptide-based therapeutics for indications including muscular dystrophy, diabetic ulcers, infectious diseases such as HIV and COVID‑19. The company has advanced at least one program to Phase II trials and has several preclinical assets; some programs have been discontinued.

Therapeutic areas: EndocrinologyNeurologyInfectious Diseases
Modalities: Synthetic peptidesSmall moleculesPeptide agonists/antagonists
Industry: Biotech

Drug pipeline

4 assets

talfirastide

Preclinical

Indications: Muscular Dystrophies

3 more assets in the full pipeline.

Request access →

Partnerships

NanOlogy LLC – collaboration on certain clinical trials/programs

Beyond the preview

Go deeper on US Biotest, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on US Biotest, Inc..

Explore the full profile